Systemic Inflammatory Response Syndrome Treatment Market Size by Therapy, Organ System, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032
8%
CAGR (2026-2032)
4.07 USD Bn.
Market Size
330
Report Pages
144
Market Tables
Overview
The Systemic Inflammatory Response Syndrome Treatment Market size was valued at USD 4.07 Billion in 2025 and the total Systemic Inflammatory Response Syndrome Treatment revenue is expected to grow at a CAGR of 8% from 2025 to 2032, reaching nearly USD 6.97 Billion by 2032.
The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The systemic inflammatory response syndrome (SIRS) describe the complex pathophysiologic response to an injury like acute inflammation, surgery, infection, trauma, burns, ischemia or reperfusion, pancreatitis, and others. SIRS is clinical response to a nonspecific onslaught of either infectious or noninfectious origin. Infection is an obtuse cause of systemic inflammatory response syndrome but, a number of additional indications including trauma, neoplasm, burn injury, ARDS, pancreatitis, and dysfunctional macrophage activation are also recognized causes.
To know about the Research Methodology :- Request Free Sample Report
Systemic Inflammatory Response Syndrome Treatment Market Drivers and Restrains
The author Kaukonen et al. in their study of over 130000 septic patients recognized that one out of eight patients in their observational study come under SIRS criteria. Global Systemic Inflammatory Response Syndrome Treatment Market Drives, Because of increase in patient admissions in hospitals and ambulatory surgical centers.
Thanks to the recognition that a diverse group of injuries created a common inflammatory response in the host and provided attractive targets for new anti-inflammatory molecules considered to provide specific treatment or to prevent further propagation. Current application of these new anti-inflammatory strategies demanded identification of early clinical markers that could be evaluated in real-time and was more likely to define a population of patients that would have a valuable response to the targeted involvement. Researchers in the field documented the importance of interrupting these inflammatory pathways as soon as possible in order to get success. If ability to recognize the septic patient at the initial phase, then this strategy was going to have a potential to produce the desired benefit. But, restricted availability of therapeutics for SIRS, lack of quality care for critically-ill patients are expected to hamper the growth of the global SIRS treatment market during the forecast period.
Manufacturers in the Systemic Inflammatory Response Syndrome Treatment are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
In terms of market segmentation, the others segment held a major share of the systemic inflammatory response syndrome treatment market in 2018. The segment is expected to dominate the market during the forecast period, because of increased penetration of treatment. On the basis of end user, the hospitals and ambulatory surgical centers segment is expected for a significant share of the global systemic inflammatory response syndrome treatment market. The hospitals and ambulatory surgical centers segment is dominate the global market during the forecast period, because of increase in inpatient admissions in hospitals and ambulatory surgical centers. However, limited availability of therapeutics for Systemic Inflammatory Response Syndrome Treatment and lack of good care for critically-ill patients are anticipated to hinder the growth of the global SIRS treatment market during the forecast period.
Systemic Inflammatory Response Syndrome Treatment Market Regional Analysis
In the global market, North America is driven primarily by increase in the occurrence of SIRS and rise in knowledge about SIRS among healthcare professionals. Furthermore, surge in government initiatives to non-infectious and infectious diseases, increase in the geriatric population that is at high risk. Large number of key players in North America focusing on research and developments activities to introduce technologically-advanced systemic inflammatory response syndrome treatments with better designs drive the market in the region. Furthermore, Europe held the second-largest dominant market in 2018. Asia Pacific is a comparatively untapped market as compared to developed regions.
The objective of the report is to present comprehensive analysis of Global Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding Global Market dynamics, structure by analyzing the market segments, and project the Global Market size. Clear representation of competitive analysis of key players by Systemic Inflammatory Response Syndrome Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Systemic Inflammatory Response Syndrome Treatment Market Scope: Inquire before buying
| Systemic Inflammatory Response Syndrome Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 4.07 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 8 % | Market Size in 2032: | USD 6.97 Bn. |
| Segments Covered: | by Therapy | Antimicrobial Therapy in SIRS Steroid Therapy in SIRS |
|
| by Organ System | Acute kidney injury Multiple organ dysfunction syndrome |
||
Systemic Inflammatory Response Syndrome Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Systemic Inflammatory Response Syndrome Treatment Market, Major Players
1. UnitedHealth Group
2. CytoSorbents Corporation
3. RegeneRx Biopharmaceuticals, Inc.
4. Endacea Inc.
5. Adrenomed AG
6. GlaxoSmithKline plc
7. Asahi Kasei Corporation
8. Cardinal Health
9. Smith &
10. Nephew plc
11. ConvaTec, Inc.
12. AstraZeneca
13. Orion Corporation
14. CHIESI Farmaceutici S.p.A.
15. Mylan N.V
Frequently Asked Questions:
1. Which region has the largest share in Global Systemic Inflammatory Response Syndrome Treatment Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Market?
Ans: The Global Market is growing at a CAGR of 8% during forecasting period 2026-2032.
3. What is scope of the Global Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – UnitedHealth Group, CytoSorbents Corporation, RegeneRx Biopharmaceuticals, Inc., Endacea Inc., Adrenomed AG, GlaxoSmithKline plc, Asahi Kasei Corporation, Cardinal Health, Smith &, Nephew plc, ConvaTec, Inc., AstraZeneca, Orion Corporation, CHIESI Farmaceutici S.p.A., and Mylan N.V.
5. What is the study period of this Market?
Ans: The Global Market is studied from 2025 to 2032.
Table of Contents
Global Systemic Inflammatory Response Syndrome Treatment Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Systemic Inflammatory Response Syndrome Treatment Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
6.1. Global Systemic Inflammatory Response Syndrome Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
7.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Type
7.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Type
7.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Type
8. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Organ System
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
8.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Organ System
8.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Organ System
8.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Organ System
9. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Indication
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
9.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Indication
9.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Indication
9.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication
10. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by End Users
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
10.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by End Users
10.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by End Users
10.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End Users
11. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Region
11.1. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Region
11.2. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Region
11.3. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Region
12. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis
12.1. Key Findings
12.2. North America Systemic Inflammatory Response Syndrome Treatment Market Overview
12.3. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
12.4. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
12.4.1. Antimicrobial Therapy in SIRS
12.4.2. Steroid Therapy in SIRS
12.5. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
12.6. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
12.6.1. Acute kidney injury
12.6.2. Multiple organ dysfunction syndrome
12.7. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
12.8. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
12.8.1. Meningitis
12.8.2. Urinary Tract Infection (UTI)
12.8.3. Pneumonia
12.8.4. Hemorrhage
12.8.5. Autoimmune Diseases
12.8.6. Others
12.9. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
12.10. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
12.10.1.1. Hospital & Ambulatory Surgical Centers
12.10.1.2. Specialty Clinics
12.10.1.3. Others
12.11. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country
12.12. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country
12.14. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
12.14.1. Antimicrobial Therapy in SIRS
12.14.2. Steroid Therapy in SIRS
12.15. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
12.15.1. Acute kidney injury
12.15.2. Multiple organ dysfunction syndrome
12.16. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
12.16.1. Meningitis
12.16.2. Urinary Tract Infection (UTI)
12.16.3. Pneumonia
12.16.4. Hemorrhage
12.16.5. Autoimmune Diseases
12.16.6. Others
12.17. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
12.17.1.1. Hospital & Ambulatory Surgical Centers
12.17.1.2. Specialty Clinics
12.17.1.3. Others
12.18. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
12.18.1. Antimicrobial Therapy in SIRS
12.18.2. Steroid Therapy in SIRS
12.19. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
12.19.1. Acute kidney injury
12.19.2. Multiple organ dysfunction syndrome
12.20. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
12.20.1. Meningitis
12.20.2. Urinary Tract Infection (UTI)
12.20.3. Pneumonia
12.20.4. Hemorrhage
12.20.5. Autoimmune Diseases
12.20.6. Others
12.21. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
12.21.1.1. Hospital & Ambulatory Surgical Centers
12.21.1.2. Specialty Clinics
12.21.1.3. Others
12.22. North America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis
12.22.1. By Type
12.22.2. By Organ System
12.22.3. By Indication
12.22.4. By End Users
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments
13. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis
13.1. Key Findings
13.2. Europe Systemic Inflammatory Response Syndrome Treatment Market Overview
13.3. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
13.4. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.4.1. Antimicrobial Therapy in SIRS
13.4.2. Steroid Therapy in SIRS
13.5. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
13.6. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.6.1. Acute kidney injury
13.6.2. Multiple organ dysfunction syndrome
13.7. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
13.8. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.8.1. Meningitis
13.8.2. Urinary Tract Infection (UTI)
13.8.3. Pneumonia
13.8.4. Hemorrhage
13.8.5. Autoimmune Diseases
13.8.6. Others
13.9. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
13.10. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.10.1.1. Hospital & Ambulatory Surgical Centers
13.10.1.2. Specialty Clinics
13.10.1.3. Others
13.11. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country
13.12. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country
13.14. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.14.1. Antimicrobial Therapy in SIRS
13.14.2. Steroid Therapy in SIRS
13.15. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.15.1. Acute kidney injury
13.15.2. Multiple organ dysfunction syndrome
13.16. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.16.1. Meningitis
13.16.2. Urinary Tract Infection (UTI)
13.16.3. Pneumonia
13.16.4. Hemorrhage
13.16.5. Autoimmune Diseases
13.16.6. Others
13.17. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.17.1.1. Hospital & Ambulatory Surgical Centers
13.17.1.2. Specialty Clinics
13.17.1.3. Others
13.18. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.18.1. Antimicrobial Therapy in SIRS
13.18.2. Steroid Therapy in SIRS
13.19. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.19.1. Acute kidney injury
13.19.2. Multiple organ dysfunction syndrome
13.20. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.20.1. Meningitis
13.20.2. Urinary Tract Infection (UTI)
13.20.3. Pneumonia
13.20.4. Hemorrhage
13.20.5. Autoimmune Diseases
13.20.6. Others
13.21. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.21.1. Hospital & Ambulatory Surgical Centers
13.21.2. Specialty Clinics
13.21.3. Others
13.22. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.22.1. Antimicrobial Therapy in SIRS
13.22.2. Steroid Therapy in SIRS
13.23. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.23.1. Acute kidney injury
13.23.2. Multiple organ dysfunction syndrome
13.24. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.24.1. Meningitis
13.24.2. Urinary Tract Infection (UTI)
13.24.3. Pneumonia
13.24.4. Hemorrhage
13.24.5. Autoimmune Diseases
13.24.6. Others
13.25. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.25.1.1. Hospital & Ambulatory Surgical Centers
13.25.1.2. Specialty Clinics
13.25.1.3. Others
13.26. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.26.1. Antimicrobial Therapy in SIRS
13.26.2. Steroid Therapy in SIRS
13.27. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.27.1. Acute kidney injury
13.27.2. Multiple organ dysfunction syndrome
13.28. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.28.1. Meningitis
13.28.2. Urinary Tract Infection (UTI)
13.28.3. Pneumonia
13.28.4. Hemorrhage
13.28.5. Autoimmune Diseases
13.28.6. Others
13.29. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.29.1.1. Hospital & Ambulatory Surgical Centers
13.29.1.2. Specialty Clinics
13.29.1.3. Others
13.30. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.30.1. Antimicrobial Therapy in SIRS
13.30.2. Steroid Therapy in SIRS
13.31. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.31.1. Acute kidney injury
13.31.2. Multiple organ dysfunction syndrome
13.32. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.32.1. Meningitis
13.32.2. Urinary Tract Infection (UTI)
13.32.3. Pneumonia
13.32.4. Hemorrhage
13.32.5. Autoimmune Diseases
13.32.6. Others
13.33. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.33.1.1. Hospital & Ambulatory Surgical Centers
13.33.1.2. Specialty Clinics
13.33.1.3. Others
13.34. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
13.34.1. Antimicrobial Therapy in SIRS
13.34.2. Steroid Therapy in SIRS
13.35. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
13.35.1. Acute kidney injury
13.35.2. Multiple organ dysfunction syndrome
13.36. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
13.36.1. Meningitis
13.36.2. Urinary Tract Infection (UTI)
13.36.3. Pneumonia
13.36.4. Hemorrhage
13.36.5. Autoimmune Diseases
13.36.6. Others
13.37. Rest Of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
13.37.1.1. Hospital & Ambulatory Surgical Centers
13.37.1.2. Specialty Clinics
13.37.1.3. Others
13.38. Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis
13.38.1. By Type
13.38.2. By Organ System
13.38.3. By Indication
13.38.4. By End Users
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments
14. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis
14.1. Key Findings
14.2. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Overview
14.3. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
14.4. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.4.1. Antimicrobial Therapy in SIRS
14.4.2. Steroid Therapy in SIRS
14.5. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
14.6. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.6.1. Acute kidney injury
14.6.2. Multiple organ dysfunction syndrome
14.7. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
14.8. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.8.1. Meningitis
14.8.2. Urinary Tract Infection (UTI)
14.8.3. Pneumonia
14.8.4. Hemorrhage
14.8.5. Autoimmune Diseases
14.8.6. Others
14.9. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
14.10. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.10.1.1. Hospital & Ambulatory Surgical Centers
14.10.1.2. Specialty Clinics
14.10.1.3. Others
14.11. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country
14.12. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country
14.14. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.14.1. Antimicrobial Therapy in SIRS
14.14.2. Steroid Therapy in SIRS
14.15. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.15.1. Acute kidney injury
14.15.2. Multiple organ dysfunction syndrome
14.16. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.16.1. Meningitis
14.16.2. Urinary Tract Infection (UTI)
14.16.3. Pneumonia
14.16.4. Hemorrhage
14.16.5. Autoimmune Diseases
14.16.6. Others
14.17. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.17.1.1. Hospital & Ambulatory Surgical Centers
14.17.1.2. Specialty Clinics
14.17.1.3. Others
14.18. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.18.1. Antimicrobial Therapy in SIRS
14.18.2. Steroid Therapy in SIRS
14.19. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.19.1. Acute kidney injury
14.19.2. Multiple organ dysfunction syndrome
14.20. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.20.1. Meningitis
14.20.2. Urinary Tract Infection (UTI)
14.20.3. Pneumonia
14.20.4. Hemorrhage
14.20.5. Autoimmune Diseases
14.20.6. Others
14.21. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.21.1.1. Hospital & Ambulatory Surgical Centers
14.21.1.2. Specialty Clinics
14.21.1.3. Others
14.22. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.22.1. Antimicrobial Therapy in SIRS
14.22.2. Steroid Therapy in SIRS
14.23. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.23.1. Acute kidney injury
14.23.2. Multiple organ dysfunction syndrome
14.24. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.24.1. Meningitis
14.24.2. Urinary Tract Infection (UTI)
14.24.3. Pneumonia
14.24.4. Hemorrhage
14.24.5. Autoimmune Diseases
14.24.6. Others
14.25. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.25.1.1. Hospital & Ambulatory Surgical Centers
14.25.1.2. Specialty Clinics
14.25.1.3. Others
14.26. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.26.1. Antimicrobial Therapy in SIRS
14.26.2. Steroid Therapy in SIRS
14.27. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.27.1. Acute kidney injury
14.27.2. Multiple organ dysfunction syndrome
14.28. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.28.1. Meningitis
14.28.2. Urinary Tract Infection (UTI)
14.28.3. Pneumonia
14.28.4. Hemorrhage
14.28.5. Autoimmune Diseases
14.28.6. Others
14.29. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.29.1.1. Hospital & Ambulatory Surgical Centers
14.29.1.2. Specialty Clinics
14.29.1.3. Others
14.30. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
14.30.1. Antimicrobial Therapy in SIRS
14.30.2. Steroid Therapy in SIRS
14.31. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
14.31.1. Acute kidney injury
14.31.2. Multiple organ dysfunction syndrome
14.32. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
14.32.1. Meningitis
14.32.2. Urinary Tract Infection (UTI)
14.32.3. Pneumonia
14.32.4. Hemorrhage
14.32.5. Autoimmune Diseases
14.32.6. Others
14.33. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
14.33.1.1. Hospital & Ambulatory Surgical Centers
14.33.1.2. Specialty Clinics
14.33.1.3. Others
14.34. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis
14.34.1. By Type
14.34.2. By Organ System
14.34.3. By Indication
14.34.4. By End Users
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments
15. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Overview
15.3. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
15.4. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
15.4.1. Antimicrobial Therapy in SIRS
15.4.2. Steroid Therapy in SIRS
15.5. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
15.6. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
15.6.1. Acute kidney injury
15.6.2. Multiple organ dysfunction syndrome
15.7. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
15.8. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
15.8.1. Meningitis
15.8.2. Urinary Tract Infection (UTI)
15.8.3. Pneumonia
15.8.4. Hemorrhage
15.8.5. Autoimmune Diseases
15.8.6. Others
15.9. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
15.10. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
15.10.1.1. Hospital & Ambulatory Surgical Centers
15.10.1.2. Specialty Clinics
15.10.1.3. Others
15.11. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country
15.12. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country
15.14. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
15.14.1. Antimicrobial Therapy in SIRS
15.14.2. Steroid Therapy in SIRS
15.15. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
15.15.1. Acute kidney injury
15.15.2. Multiple organ dysfunction syndrome
15.16. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
15.16.1. Meningitis
15.16.2. Urinary Tract Infection (UTI)
15.16.3. Pneumonia
15.16.4. Hemorrhage
15.16.5. Autoimmune Diseases
15.16.6. Others
15.17. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
15.17.1.1. Hospital & Ambulatory Surgical Centers
15.17.1.2. Specialty Clinics
15.17.1.3. Others
15.18. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
15.18.1. Antimicrobial Therapy in SIRS
15.18.2. Steroid Therapy in SIRS
15.19. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
15.19.1. Acute kidney injury
15.19.2. Multiple organ dysfunction syndrome
15.20. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
15.20.1. Meningitis
15.20.2. Urinary Tract Infection (UTI)
15.20.3. Pneumonia
15.20.4. Hemorrhage
15.20.5. Autoimmune Diseases
15.20.6. Others
15.21. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
15.21.1.1. Hospital & Ambulatory Surgical Centers
15.21.1.2. Specialty Clinics
15.21.1.3. Others
15.22. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
15.22.1. Antimicrobial Therapy in SIRS
15.22.2. Steroid Therapy in SIRS
15.23. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
15.23.1. Acute kidney injury
15.23.2. Multiple organ dysfunction syndrome
15.24. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
15.24.1. Meningitis
15.24.2. Urinary Tract Infection (UTI)
15.24.3. Pneumonia
15.24.4. Hemorrhage
15.24.5. Autoimmune Diseases
15.24.6. Others
15.25. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
15.25.1.1. Hospital & Ambulatory Surgical Centers
15.25.1.2. Specialty Clinics
15.25.1.3. Others
15.26. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis
15.26.1. By Type
15.26.2. By Organ System
15.26.3. By Indication
15.26.4. By End Users
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments
16. South America Systemic Inflammatory Response Syndrome Treatment Market Analysis
16.1. Key Findings
16.2. South America Systemic Inflammatory Response Syndrome Treatment Market Overview
16.3. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type
16.4. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
16.4.1. Antimicrobial Therapy in SIRS
16.4.2. Steroid Therapy in SIRS
16.5. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System
16.6. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
16.6.1. Acute kidney injury
16.6.2. Multiple organ dysfunction syndrome
16.7. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication
16.8. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
16.8.1. Meningitis
16.8.2. Urinary Tract Infection (UTI)
16.8.3. Pneumonia
16.8.4. Hemorrhage
16.8.5. Autoimmune Diseases
16.8.6. Others
16.9. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users
16.10. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
16.10.1.1. Hospital & Ambulatory Surgical Centers
16.10.1.2. Specialty Clinics
16.10.1.3. Others
16.11. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country
16.12. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country
16.14. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
16.14.1. Antimicrobial Therapy in SIRS
16.14.2. Steroid Therapy in SIRS
16.15. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
16.15.1. Acute kidney injury
16.15.2. Multiple organ dysfunction syndrome
16.16. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
16.16.1. Meningitis
16.16.2. Urinary Tract Infection (UTI)
16.16.3. Pneumonia
16.16.4. Hemorrhage
16.16.5. Autoimmune Diseases
16.16.6. Others
16.17. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
16.17.1.1. Hospital & Ambulatory Surgical Centers
16.17.1.2. Specialty Clinics
16.17.1.3. Others
16.18. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
16.18.1. Antimicrobial Therapy in SIRS
16.18.2. Steroid Therapy in SIRS
16.19. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
16.19.1. Acute kidney injury
16.19.2. Multiple organ dysfunction syndrome
16.20. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
16.20.1. Meningitis
16.20.2. Urinary Tract Infection (UTI)
16.20.3. Pneumonia
16.20.4. Hemorrhage
16.20.5. Autoimmune Diseases
16.20.6. Others
16.21. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
16.21.1.1. Hospital & Ambulatory Surgical Centers
16.21.1.2. Specialty Clinics
16.21.1.3. Others
16.22. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type
16.22.1. Antimicrobial Therapy in SIRS
16.22.2. Steroid Therapy in SIRS
16.23. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System
16.23.1. Acute kidney injury
16.23.2. Multiple organ dysfunction syndrome
16.24. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication
16.24.1. Meningitis
16.24.2. Urinary Tract Infection (UTI)
16.24.3. Pneumonia
16.24.4. Hemorrhage
16.24.5. Autoimmune Diseases
16.24.6. Others
16.25. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users
16.25.1.1. Hospital & Ambulatory Surgical Centers
16.25.1.2. Specialty Clinics
16.25.1.3. Others
16.26. South America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis
16.26.1. By Type
16.26.2. By Organ System
16.26.3. By Indication
16.26.4. By End Users
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments
17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. UnitedHealth Group
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Company Footprint
17.3.2. CytoSorbents Corporation
17.3.3. RegeneRx Biopharmaceuticals, Inc.
17.3.4. Endacea Inc.
17.3.5. Adrenomed AG
17.3.6. GlaxoSmithKline plc
17.3.7. Asahi Kasei Corporation
17.3.8. Cardinal Health
17.3.9. Smith &
17.3.10. Nephew plc
17.3.11. ConvaTec, Inc.
17.3.12. AstraZeneca
17.3.13. Orion Corporation
17.3.14. CHIESI Farmaceutici S.p.A.
17.3.15. Mylan N.V
18. Primary Key Insights